Leading Polish biotech opens new research site

17 May 2017

Selvita (WSE: SLV), a leading Poland-based research focussed drugmaker, has opened a new research site in Poznan, Poland.

The new site is located in the Wielkopolska Center of Advanced Technologies and the initial laboratory space which Selvita occupies amounts to 5 400 sq feet, which constitutes nearly 20% increase in Selvita laboratory space compared to the current state, with significant extension possibilities.

Biotech firm Selvita plans to employ up to 50 researchers in the first months of Poznan site operations, and successively increase both the employment, as well as research space.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK